What publications has Paul Cox authored on neurocept-like molecules or therapies?
Executive summary
Paul Alan Cox has publicly promoted research into neurodegenerative toxins (notably BMAA) and the therapeutic potential of L‑serine, and he leads Brain Chemistry Labs which lists related news, videos and profiles [1] [2]. Available sources show media profiles, interviews and organizational pages describing his work and trials, but they do not provide a definitive, itemized bibliography of peer‑reviewed publications specifically labelled “neurocept‑like molecules or therapies” authored by Cox (available sources do not mention a complete publication list on this topic) [2] [1] [3].
1. What the public record emphasizes: toxin → serine hypothesis
Reporting and Brain Chemistry Labs materials foreground Cox’s theory that the cyanobacterial toxin BMAA contributed to Guam’s neurodegenerative disease cluster and that L‑serine could be protective; Fortune and Brain Chemistry Labs videos summarize that line of work and its translation toward clinical trials [3] [1]. Those pieces describe his lab’s animal and observational data and his move to file trials with regulators, but they are journalistic summaries rather than a citation list of primary research papers [3] [1].
2. Institutional pages and interviews, not a formal bibliography
Brain Chemistry Labs’ website hosts Cox’s profile, news posts and videos that describe ongoing programs — diagnostic tests for ALS and investigations into L‑serine — and highlight collaborators and press coverage [2] [4] [1]. Those pages present research claims and institutional goals (for example, making a diagnostic test available) but do not enumerate peer‑review citations or a curated list titled “neurocept” or “neurocept‑like molecules” authored by Cox [2] [4].
3. Major media profiles summarize his work but are not primary sources
Fortune’s longform profile traces Cox’s fieldwork, biochemical hypotheses about BMAA and his promotion of L‑serine as a therapy candidate; it quotes colleagues and describes lab efforts and trial plans [3]. Good News Network and other outlets likewise recap his proposed translation from ethnobotany to therapeutics [5]. These are useful for context and claims verification, but they are secondary reporting—not a replacement for a list of Cox’s original, peer‑reviewed publications [3] [5].
4. Scholarly databases indicate Cox’s authorship record but require direct inspection
Google Scholar and ResearchGate entries tied to “Paul Cox” indicate a substantial corpus (hundreds of works and thousands of citations) and list topics including ALS and Alzheimer’s, implying that Cox has authored scientific articles relevant to neurodegeneration [6] [7]. However, the specific documents, dates and whether they use the term “neurocept” or describe “neurocept‑like” molecules are not provided in the available search results; locating a definitive publication list requires inspecting those scholarly profiles directly [6] [7].
5. What is explicitly verifiable in the current sources
- Brain Chemistry Labs and affiliated profiles confirm Cox’s role as Executive Director and his research focus on neurodegenerative illness, L‑serine, and diagnostics for ALS and Alzheimer’s [2] [8].
- Multiple interviews and features document his BMAA hypothesis and the lab’s move toward clinical trials of L‑serine [3] [1] [5].
These claims are documented in media and organizational materials but do not substitute for a formal bibliography of peer‑reviewed work by title and journal [2] [3] [1].
6. Competing perspectives and limitations in the coverage
Media pieces present Cox’s theory and ambitions; they also note that he is not a neurologist and that his arguments have attracted scientific debate (Fortune emphasizes his outsider status and divergent interpretations) [3]. Available sources do not provide systematic critiques from independent peer‑reviewed literature or consensus statements about the efficacy of L‑serine in humans (available sources do not mention independent consensus reviews) [3].
7. Practical next steps to get an authoritative list
To compile a precise, publication‑level answer you should: (a) open Cox’s Google Scholar profile and ResearchGate entries shown in the results to extract article titles and DOIs [6] [7]; (b) query PubMed or Scopus for “Paul Alan Cox” plus keywords “BMAA,” “L‑serine,” “Alzheimer,” “ALS” to capture peer‑reviewed papers; and (c) cross‑check Brain Chemistry Labs’ news and CV page for a formal bibliography [2] [1] [6]. The sources provided here point to where those records live but do not themselves supply the comprehensive list you asked for [2] [6].
Summary: Available reporting and institutional pages confirm Paul Alan Cox’s leadership of work on BMAA and L‑serine and note trials and diagnostics in progress, but the current sources do not include a ready, itemized bibliography of peer‑reviewed publications on “neurocept‑like” molecules or therapies authored by Cox; you’ll need to consult his Google Scholar/ResearchGate/PubMed profiles linked above for a definitive list [6] [7] [2].